Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: HIMS stock price vs AEHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AEHR's multiple
Needs AEHR P/E.
Implied fair value · at HIMS's multiple
Needs EPS (TTM) is negative, HIMS P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HIMS FY 2025 (ended Dec 31, 2025) · AEHR FY 2026 (ended May 29, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HIMS & HERS HEALTH, INC. · implied price per share
Bear
-$3.14
Base
-$3.69
Bull
-$4.25
AEHR TEST SYSTEMS · implied price per share
Bear
$0.77
Base
$0.91
Bull
$1.05
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
2.48x
0.01x
Net debt / EBITDA
Leverage against operating earnings
7.54x
16.67x
Cash and equivalents
Liquid reserves on the balance sheet
$228.62M
$134.21M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Teladoc Health, Inc.
HIMS vs TDOC
GoodRx Holdings, Inc.
HIMS vs GDRX
CLOVER HEALTH INVESTMENTS, CORP. /DE
HIMS vs CLOV
Roivant Sciences Ltd.
HIMS vs ROIV
TERADYNE, INC
HIMS vs TER
Merck & Co., Inc.
HIMS vs MRK
LAM RESEARCH CORP
HIMS vs LRCX
APPLIED MATERIALS INC /DE
HIMS vs AMAT
SKYWORKS SOLUTIONS, INC.
HIMS vs SWKS
LATTICE SEMICONDUCTOR CORP
HIMS vs LSCC
$1.34B
$2.71M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
